Japanese patient preferences regarding intermediate to advanced hepatocellular carcinoma treatments

References

• Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28(5):753–770. doi:10.1016/j.bpg.2014.08.00725260306
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan 2000. Int J Cancer. 2001;94:153–156.11668491
   PubMed Web of Science ®Google Scholar
• Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis. 2005;25(2):143–154. doi:10.1055/s-2005-87119415918143
   PubMed Web of Science ®Google Scholar
• Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer. 2015;4(1):39–50. doi:10.1159/00036772726020028
   PubMed Web of Science ®Google Scholar
• Umemura T, Ichijo T, Yoshizawa K, et al. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44(Suppl 19):102. doi:10.1007/s00535-008-2251-019148802
   PubMed Web of Science ®Google Scholar
• Bruix J, Llovet J. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2001;35(3):519–524. doi:10.1053/jhep.2002.32089
   Web of Science ®Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–853. doi:10.1053/j.gastro.2015.12.04126795574
   PubMed Web of Science ®Google Scholar
• Kudo M, Matsui O, Izumi N, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer. 2014;3:458‐68. doi:10.1159/000343875
   Web of Science ®Google Scholar
• American Society of Clinical Oncology (ASCO). In: liver cancer: treatment options. Cancer.Net editorial board; 2016 http://www.cancer.net/cancer-types/liver-cancer/treatment-options. Accessed 220, 2017.
   Google Scholar
• Eek D, Krohe M, Mazar I, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609–1621. doi:10.2147/PPA.S10662927601886
   PubMed Web of Science ®Google Scholar
• Zdenkowski N, Butow P, Hutchings E, Douglas C, Coll JR, Boyle FM. A decision aid for women considering neoadjuvant systemic therapy for operable invasive breast cancer: development and protocol of a phase II evaluation study (ANZ1301 DOMINO). JMIR Res Protoc. 2016;5(2):e88. doi:10.2196/resprot.564127207563
   PubMedGoogle Scholar
• Flynn TN. Valuing citizen and patient preferences in health: recent developments in three types of best-worst scaling. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):259–267. doi:10.1586/erp.10.2920545591
   PubMed Web of Science ®Google Scholar
• Gallego G, Bridges J, Flynn T, Blauvelt BM, Niessen LW. Using best-worst scaling in horizon scanning for hepatocellular carcinoma technologies. Int J Technol Assess Health Care. 2012;28(3):339–346. doi:10.1017/S026646231200027X22980714
   PubMed Web of Science ®Google Scholar
• Ogasawara S, Chiba T, Ooka Y, et al. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs. 2015;33(3):729–739. doi:10.1007/s10637-015-0237-325861764
   PubMed Web of Science ®Google Scholar
• Ogasawara S, Chiba T, Ooka Y, et al. Liver function assessment according to the Albumin–bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma. Invest New Drugs. 2015;33(6):1257–1262. doi:10.1007/s10637-015-0292-926462681
   PubMed Web of Science ®Google Scholar
• Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol. 2009;10(5):425–434. doi:10.3348/kjr.2009.10.5.42519721826
   PubMed Web of Science ®Google Scholar
• Cao W, Li J, Hu C, et al. TACE symptom clusters and symptom interference of HCC patients undergoing TACE: a cross-sectional study in China. Support Care Cancer. 2013;21(2):475–483. doi:10.1007/s00520-012-1541-523010958
   PubMed Web of Science ®Google Scholar
• Clark T. Complications of hepatic chemoembolization. Semin Intervent Radiol. 2006;23(2):119–125. doi:10.1055/s-2006-94144221326755
   PubMedGoogle Scholar
• Ikeda M, Arai Y, Park SJ, et al. Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. J Vasc Interv Radiol. 2013;24:490–500. doi:10.1016/j.jvir.2013.01.00323466316
   PubMed Web of Science ®Google Scholar
• Ganeshan A, Upponi S, Lye-Quen H, Warakaulle D, Uberoi R. Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol. 2008;19:847–851. doi:10.1093/annonc/mdm52818029972
   PubMed Web of Science ®Google Scholar
• Oh MJ, Lee HJ, Lee SH. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy 2013. Clin Mol Hepatol. 2013;19:288–299. doi:10.3350/cmh.2013.19.3.28824133667
   PubMedGoogle Scholar
• Arizumi T, Ueshima K, Iwanishi M, et al. Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience second analysis. Dig Dis. 2015;33(6):728–734. doi:10.1159/00043907926488730
   PubMed Web of Science ®Google Scholar
• Bruix J, Raoul JL, Sherman M. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalysis of a phase III trial. J Hepatol. 2012;57:821–829. doi:10.1016/j.jhep.2012.06.01422727733
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. for the SHARP investigators study group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390. doi:10.1056/NEJMoa070885718650514
   PubMed Web of Science ®Google Scholar
• Louviere JJ, Flynn TN, Marley AAJ. Best-Worst Scaling: Theory, Methods and Applications. University Printing House: Cambridge University Press; 2015.
   Google Scholar
• Molinari M, De Coutere S, Krahn M, Helton S, Urbach DR. Patients‘ preferences and trade-offs for the treatment of early stage hepatocellular carcinoma. J Surg Res. 2014;189(1):57–67. doi:10.1016/j.jss.2014.02.01524650457
   PubMed Web of Science ®Google Scholar
• Hifinger M, Hiligsmann M, Ramiro S, et al. Patients‘ preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists. Rheumatology (Oxford). 2017;56(1):68–76. doi:10.1093/rheumatology/kew32828028156
   PubMed Web of Science ®Google Scholar
• Sato K, Sato T, Furuse J, et al. A conundrum for randomized controlled trials: experience from a small hepatocellular carcinoma trial. Jpn J Clin Oncol. 2010;40(10):949–953. doi:10.1093/jjco/hyq07420495193
   PubMed Web of Science ®Google Scholar
• Harder H, Ballinger R, Langridge C, Ring A, Fallowfield LJ. Adjuvant chemotherapy in elderly women with breast cancer: patients‘ perspectives on information giving and decision making. Psychooncology. 2013;22(12):2729–2735. doi:10.1002/pon.333823813806
   PubMed Web of Science ®Google Scholar
• Farinati F, Gianni S, Marin G, Fagiuoli S, Rinaldi M, Naccarato R. Does the choice of treatment influence survival of patients with small hepatocellular carcinoma in compensated cirrhosis? Eur J Gastroenterol Hepatol. 2001;13(10):1217–1224.11711779
   PubMed Web of Science ®Google Scholar
• Chen CM, Hsu CY, Bai CH Building a patient oriented treatment decision system for liver cancer. 2012 3rd Global Congress on Intelligent Systems; 2012; Wuhan, China.
   Google Scholar
• Nexavar® (Sorafenib) [Package Insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; 2010.
   Google Scholar
• Minami T, Tateishi R, Shiina S, et al. Comparison of improved prognosis between hepatitis B- and hepatitis C-related hepatocellular carcinoma. Hepatol Res. 2015;45:E99–E107. doi:10.1111/hepr.1246825559860
   PubMed Web of Science ®Google Scholar